Bavarian Nordic announced has entered into an agreement with Emergent BioSolutions, to acquire two marketed travel vaccines, Vivotif for the prevention of typhoid fever and Vaxchora against cholera as well as a Phase 3 vaccine candidate for the prevention of Chikungunya virus for a price tag of up to $380 million, including $270 million in an upfront payment and up to $110 million in future conditional milestone payments.
The acquisition also includes facilities and key personnel related to the acquired assets.
